Publications and Presentations

Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.

Fröberg G, Maurer FP, Chryssanthou E, Fernström L, Benmansour H, Boarbi S, Mengshoel AT, Keller PM, Viveiros M, Machado D, Fitzgibbon MM, Mok S, Werngren J, Cirillo DM, Alcaide F, Hyyryläinen HL, Aubry A, Andres S, Nadarajan D, Svensson E, Turnidge J, Giske CG, Kahlmeter G, Cambau E, van Ingen J, Schön T; EUCAST AMST and ESCMYC study groups. Clin Microbiol Infect. 2023 Jun;29(6):758-764. doi: 10.1016/j.cmi.2023.02.007. 

Go to publication

The EUCAST approach for drug susceptibility testing of mycobacteria: past, present, future.

Prof Emmanuelle CAMBAU, MD, PhD University Paris Cité, INSERM, APHP GHU Nord Bichat Hospital, Paris, National reference center for mycobacteria , France Chair of the Antimycobacterial susceptibility testing subcommittee of EUCAST. ECCMID 2022.

Go to presentation

What is the role of the EUCAST reference method for MIC testing of the Mycobacterium tuberculosis complex?

Thomas Schön, Claudio Umberto Köser, Jim Werngren, Miguel Viveiros, Sophia Georghiou, Gunnar Kahlmeter, Christian Giske, Florian Maurer, Gerard Lina, John Turnidge, Jakko van Ingen, Mateja Jankovic, Delia Goletti, Daniela Maria Cirillo, Miguel Santin, Emmanuelle Cambau, on behalf of ESGMYC. 5 August 2020. https://doi.org/10.1016/j.cmi.2020.07.037 

Go to publication

Multicentre testing of the EUCAST broth microdilution reference method for MIC determination on Mycobacterium tuberculosis.

Thomas Schön, Jim Werngren, Diana Machado, Emanuele Borroni, Maria Wijkander, Gerard Lina, Johan Mouton, Erika Matuschek, Gunnar Kahlmeter, Christian Giske, Miguel Santin, Daniela Maria Cirillo, Miguel Viveiros, Emmanuelle Cambau. 23 October 2020. https://doi.org/10.1016/j.cmi.2020.10.019

Go to publication

Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex isolates e the EUCAST broth microdilution reference method for MIC determination.

Thomas Schön, Jim Werngren, Diana Machado, Emanuele Borroni, Maria Wijkander, Gerard Lina, Johan Mouton, Erika Matuschek, Gunnar Kahlmeter, Christian Giske, Miguel Santin, Daniela Maria Cirillo, Miguel Viveiros, Emmanuelle Cambau. 1 August 2020. https://doi.org/10.1016/j.cmi.2020.07.036

Go to publication

Mycobacterium tuberculosis drug-resistance testing: challenges, recent developments and perspectives.

T. Schön, P. Miotto, C.U. Köser, M. Viveiros, E. Böttger, E. Cambau. 1 November 2016. https://doi.org/10.1016/j.cmi.2016.10.022

Go to publication

Susceptibility testing breakpoints for Mycobacterium tuberculosis categorize isolates with resistance mutations in gyrA as susceptible to fluoroquinolones: implications for MDR-TB treatment and the definition of XDR-TB.

Niward K, Ängeby K, Chryssanthou E, Paues J, Bruchfeld J, Jureen P, Giske CG, Kahlmeter G, Schön T. J Antimicrob Chemother. 2016 Feb;71(2):333–338. doi: 10.1093/jac/dkv353. Epub 2015 Nov 3. PMID: 26538509

Go to publication

Little difference between minimum inhibitory concentrations of Mycobacterium tuberculosis wild-type organisms determined with BACTEC MGIT 960 and Middlebrook 7H10.

Sturegård E, Ängeby KA, Werngren J, Juréen P, Kronvall G, Giske CG, Kahlmeter G, Schön T. Clin Microbiol Infect. 2015 Feb;21(2):148.e5–7. doi: 10.1016/j.cmi.2014.08.021. Epub 2014 Oct 29. PMID: 25640156. Free article

Go to publication

Rifampicin-resistant and rifabutin-susceptible Mycobacterium tuberculosis strains: a breakpoint artefact?

Schön T, Juréen P, Chryssanthou E, Giske CG, Kahlmeter G, Hoffner S, Ängeby K. J Antimicrob Chemother. 2013 Sep;68(9):2074–2077. doi: 10.1093/jac/dkt150. Epub 2013 Apr 30. PMID: 23633684

Go to publication

Challenging a dogma: antimicrobial susceptibility testing breakpoints for Mycobacterium tuberculosis.

Ängeby K, Juréen P, Kahlmeter G, Hoffner SE, Schön T. Bull World Health Organ. 2012 Sep 1;90(9):693–698. doi: 10.2471/BLT.11.096644. Epub 2012 May 29. PMID: 22984314. Free PMC article

Go to publication

Wild-type distributions of seven oral second-line drugs against Mycobacterium tuberculosis.

Schön T, Juréen P, Chryssanthou E, Giske CG, Sturegård E, Kahlmeter G, Hoffner S, Ängeby KA. Int J Tuberc Lung Dis. 2011 Apr;15(4):502–509. doi: 10.5588/ijtld.10.0238. PMID: 21396210

Go to publication

Wild-type MIC distributions of four fluoroquinolones active against Mycobacterium tuberculosis in relation to current critical concentrations and available pharmacokinetic and pharmacodynamic data.

Ängeby KA, Juréen P, Giske CG, Chryssanthou E, Sturegård E, Nordvall M, Johansson AG, Werngren J, Kahlmeter G, Hoffner SE, Schön T. J Antimicrob Chemother. 2010 May;65(5):946–952. doi: 10.1093/jac/dkq091. Epub 2010 Mar 23. PMID: 20332195

Go to publication

Wild-type MIC distributions for aminoglycoside and cyclic polypeptide antibiotics used for treatment of Mycobacterium tuberculosis infections.

Juréen P, Ängeby K, Sturegård E, Chryssanthou E, Giske CG, Werngren J, Nordvall M, Johansson A, Kahlmeter G, Hoffner S, Schön T.
J Clin Microbiol. 2010 May;48(5):1853–1858. doi: 10.1128/JCM.00240-10. Epub 2010 Mar 17. PMID: 20237102. Free PMC article

Go to publication